慢性髓性白血病中新型酪氨酸激酶抑制剂的突变分析及克服伊马替尼耐药性 - Suppr

Suppr

超能文献

Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.

作者信息

Mauro Michael J

机构信息

Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR 97239, USA.

出版信息

Curr Treat Options Oncol. 2007 Aug;8(4):287-95. doi: 10.1007/s11864-007-0036-y.

DOI:10.1007/s11864-007-0036-y

PMID:18157514

Abstract

摘要

相似文献

Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.

Curr Treat Options Oncol. 2007 Aug;8(4):287-95. doi: 10.1007/s11864-007-0036-y.

Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.

Leuk Lymphoma. 2009 Dec;50(12):2092-5. doi: 10.3109/10428190903332486.

3. Imatinib therapy in chronic myelogenous leukemia.

Intern Med. 2007;46(2):95-7. doi: 10.2169/internalmedicine.46.1781. Epub 2007 Jan 15.

New tyrosine kinase inhibitors in chronic myeloid leukemia.

Haematologica. 2005 Apr;90(4):534-41.

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.

Pharmacogenomics. 2012 Aug;13(11):1271-84. doi: 10.2217/pgs.12.103.

Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.

Pol Arch Med Wewn. 2009 Dec;119(12):789-94.

ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.

Haematologica. 2011 Feb;96(2):342-3. doi: 10.3324/haematol.2010.036673. Epub 2010 Dec 29.

Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.

Genet Test Mol Biomarkers. 2010 Feb;14(1):67-74. doi: 10.1089/gtmb.2009.0126.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Leukemia. 2002 Nov;16(11):2190-6. doi: 10.1038/sj.leu.2402741.

Chronic myeloid leukemia: advances in diagnosis and management.

JAAPA. 2013 Feb;26(2):26-9. doi: 10.1097/01720610-201302000-00005.

引用本文的文献

Chronic myeloid leukemia: mechanisms of resistance and treatment.

Hematol Oncol Clin North Am. 2011 Oct;25(5):981-95, v. doi: 10.1016/j.hoc.2011.09.004. Epub 2011 Oct 19.

本文引用的文献

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Blood. 2007 Nov 15;110(10):3540-6. doi: 10.1182/blood-2007-03-080689. Epub 2007 Aug 22.

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

Blood. 2007 Jun 15;109(12):5143-50. doi: 10.1182/blood-2006-11-056028. Epub 2007 Feb 22.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

N Engl J Med. 2006 Dec 7;355(23):2408-17. doi: 10.1056/NEJMoa062867.

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

Blood. 2007 Mar 15;109(6):2303-9. doi: 10.1182/blood-2006-09-047266. Epub 2006 Nov 30.

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

Blood. 2007 Jan 1;109(1):306-14. doi: 10.1182/blood-2006-03-013250. Epub 2006 Sep 5.

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

N Engl J Med. 2006 Jun 15;354(24):2542-51. doi: 10.1056/NEJMoa055104.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Blood. 2006 Sep 15;108(6):1809-20. doi: 10.1182/blood-2006-02-005686. Epub 2006 May 18.

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.

Blood. 2006 Jul 15;108(2):697-704. doi: 10.1182/blood-2005-11-4687. Epub 2006 Apr 4.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Blood. 2006 Jul 1;108(1):28-37. doi: 10.1182/blood-2006-01-0092. Epub 2006 Mar 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验